A Single Center's Experience with Candida parapsilosis Related Long-Term Central Venous Access Device Infections: The Port Removal Decision and Its Outcomes

REFERENCES

• Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect. 2006;12(7):606–620.
   PubMed Web of Science ®Google Scholar
• Ozdemir H, Karbuz A, Ciftçi E, Treatment of central venous catheter infection due Candida lipolytica by caspofungin-lock therapy. Mycoses. 2011;54(5):647–649.
   PubMed Web of Science ®Google Scholar
• Van Burik JH, Leisenring W, Myerson D, The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine. 1998;77:246–254.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 2002;40:3551–3557.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Greves HM, Lautenbach E, Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004;23(7):635–641.
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Fegeler W, Rellensmann G, Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect. 2012;18(2):27–30.
   PubMed Web of Science ®Google Scholar
• Neu N, Malik M, Lunding A, Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr Infect Dis J. 2009;28(9):806–809.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Martino P, De Bernadis F, Rising incidence of Candida parapsilosis fungemia in patients with haematologic malignancies: clinical aspects, predisposing factors and differential. Clin Infect Dis. 1996;23(3):506–514.
   PubMed Web of Science ®Google Scholar
• Levy I, Rubin LG, Vasishtha S, Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis. 1998;26:1086–1088.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–189.
   PubMed Web of Science ®Google Scholar
• Posteraro B, Bruno S, Boccia S, Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect Control Hosp Epidemiol. 2004;25:641–645.
   PubMed Web of Science ®Google Scholar
• Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21(4):606–625.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535.
   PubMed Web of Science ®Google Scholar
• Hope WW, Castagnola E, Groll AH, ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(Suppl 7):38–52.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, de Moraes AB, Zanini RR, Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol. 2007;28(7):799–804.
   PubMed Web of Science ®Google Scholar
• Hawser SP, Douglas LG. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother. 1995;39:2128–2131.
   PubMed Web of Science ®Google Scholar
• Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11:30–36.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocan- dins. Antimicrob Agents Chemother. 2002;46:1773– 1780.
   PubMed Web of Science ®Google Scholar
• Bachmann SP, Vandewalle K, Ramage G, In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46;3591–3596.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Posteraro B, Trecarichi EM, Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007;45:1843–1850.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Results from the Artemis Disk. Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735–1745.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol. 2003;41:5729–5731.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol. 2003;41:1440–1446.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Spreghini E, Tomassetti S, Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006;50: 2719–2727.
   PubMed Web of Science ®Google Scholar
• Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007;59:767–771.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773–1780.
   PubMed Web of Science ®Google Scholar
• Marco FC, Danes M, Almela A, Trends in frequency and in vitro susceptibilities to antifungal agents, including vori- conazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996–2001). Diagn Microbiol Infect Dis. 2003;46:259–264.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp, including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425–5427.
   PubMed Web of Science ®Google Scholar